



25 March 2024

Life sciences, pharmaceutical and consumer health products Company, Bioxyne Limited (ASX Code: BXN) ("Bioxyne" or the "Company") is pleased to invite shareholders and investors to an investor webinar on Thursday, 28 March at 10:15 am AEDT / 7:15 am AWST, where Managing Director, Sam Watson, will provide a company update and engage in a Q&A session.

Event: BXN Investor Webinar

Presenter: Managing Director, Sam Watson

Time: Thursday, 28 March at 10:15 am AEDT / 7:15 am AWST

Where: Zoom Webinar, details to be provided upon registration. To register your interest for the webinar, please click through to the link below.

Registration link:

https://janemorganmanagementau.zoom.us/webinar/register/WN raP08w8rTTS Hb2vEx8h8A

After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the Panel throughout the presentation, given this is a pre-recorded webinar we highly encourage attendees to send through questions via email beforehand to jm@janemorganmanagement.com.au.

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Jane Morgan Investor and Media Relations Bioxyne Limited jm@janemorganmanagement.com.au Jason Hine
Chief Operating Officer
Bioxyne Limited
jason@breathelifesciences.com

P: +61 2 9078 8180

W: www.bioxyne.com



Suite 506, Level 5, 50 Clarence St Sydney NSW 2000

P: +61 2 9078 8180 **W:** www.bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow.

Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- (a) owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- (b) contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- (c) white label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- (d) research and development for third party customers; and
- (e) direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson® (drwatsoncbd.com, nolcbn.com, drwatsoncbd.de)

P: +61 2 9078 8180

W: www.bioxyne.com

Corporate: https://bioxyne.com

Australia: https://bls.com.au; https://blsclinics.com.au;

International: https://breathelifesciences.com

Dr Watson (UK and EU only): drwatsoncbd.com; drwatsoncbd.de; nolcbn.com